Skip to content


Tagrisso (osimertinib) is a small molecule pharmaceutical. Osimertinib was first approved as Tagrisso on 2015-11-13. It is used to treat non-small-cell lung carcinoma in the USA. It has been approved in Europe to treat non-small-cell lung carcinoma. It is known to target epidermal growth factor receptor. Tagrisso's patent is valid until 2035-01-02 (FDA).
Trade Name Tagrisso
Common Name Osimertinib
Indication non-small-cell lung carcinoma
Drug Class Tyrosine kinase inhibitors: epidermal growth factor receptor (EGFR) inhibitors
Get full access now